GleamWall
中文EN

ANVS Annovis Bio, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1477845 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-107.9%
TTM EPS YoY-8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-455.9%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets340.5%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio36.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$25.22M$20.00M
SG&A expense$4.48M$6.70M
Operating income-$29.70M-$26.69M
Income tax$0—
Net income-$28.85M-$24.59M
EPS (basic)-1.40-2.02
EPS (diluted)-1.40-2.31
Weighted avg. shares (diluted)20.55M12.24M
Balance sheet
Cash & equivalents$19.53M$10.55M
Total assets$21.08M$13.93M
Current liabilities$3.64M$3.88M
Total liabilities$4.23M$4.62M
Shareholders' equity$16.85M$9.31M
Shares outstanding27.20M14.14M
Cash flow statement
Operating cash flow-$25.62M-$21.89M
Financing cash flow$34.60M$26.69M
Stock-based compensation$1.80M$3.84M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.